

The clinical significance of antiphospholipid antibodies

European Journal of Rheumatology

3, 75-84

DOI: [10.5152/eurjrheum.2015.0085](https://doi.org/10.5152/eurjrheum.2015.0085)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Utility of thrombophilia testing in patients with venous thrombo-embolism. <i>Journal of Thoracic Disease</i> , 2016, 8, 3697-3703.	1.4	11
2	The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus. <i>Reumatismo</i> , 2016, 68, 137-143.	0.9	14
4	Neurological and Neurosurgical Emergencies in Patients with Hematological Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 24.	4.2	1
5	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. <i>Lupus Science and Medicine</i> , 2017, 4, e000225.	2.7	18
6	Clinical relevance of silent red blood cell autoantibodies. <i>Haematologica</i> , 2017, 102, e473-e475.	3.5	9
7	The Influence of Income and Formal Education on Damage in Brazilian Patients With Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 246-251.	0.9	7
8	Kidney involvement in antiphospholipid syndrome – current diagnostic and management problems. <i>Reumatologia</i> , 2017, 55, 213-214.	1.1	5
9	Nephropathy in Pparg-null mice highlights PPAR β systemic activities in metabolism and in the immune system. <i>PLoS ONE</i> , 2017, 12, e0171474.	2.5	34
10	Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus. <i>Rheumatology</i> , 2018, 57, 1350-1357.	1.9	28
11	Threatening biomarkers in lupus pregnancy: Biochemistry and genetic challenges. <i>Frontiers in Biology</i> , 2018, 13, 28-35.	0.7	5
12	Retinal Manifestations of Renal Diseases. , 2018, , 67-78.		0
13	Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 629-639.	1.8	20
14	Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 665-669.	1.6	14
15	The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 920-927.	1.7	6
16	Antiphospholipid Antibody Positivity and the Clinical Outcomes of Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatic Diseases</i> , 2018, 25, 239.	1.1	3
17	Zonal cortical scarring and tubular thyroidization in kidney biopsies of patients with SLE – histologic indicator for antiphospholipid antibodies. <i>Lupus</i> , 2018, 27, 2236-2244.	1.6	5
18	Autoimmune haemolytic anaemia and autoimmune thrombocytopenia in childhood-onset systemic lupus erythematosus: updates on pathogenesis and treatment. <i>Current Opinion in Rheumatology</i> , 2018, 30, 498-505.	4.3	16
19	Obstetric antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2018, 5, e000197.	2.7	42

#	ARTICLE	IF	CITATIONS
20	Multiple embolic strokes as a result of Libmanâ€™Sacks endocarditis associated with lupus and secondary antiphospholipid antibody syndrome: a case report. <i>European Heart Journal - Case Reports</i> , 2018, 2, yty094.	0.6	3
21	Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 2010-2021.	27.0	503
22	Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. <i>Frontiers in Medicine</i> , 2018, 5, 161.	2.6	42
23	Clinical implications of systemic lupus erythematosus without and with antiphospholipid syndrome in peri- and postmenopausal age. <i>Przegląd Menopauzalny</i> , 2018, 17, 86-90.	1.3	4
24	Maternal Medical Disorders of Fetal Significance. , 2018, , 104-118.e3.		0
25	Gastric neuroendocrine tumour, atrophic gastritis and autoimmune haemolytic anaemia: a case report and review. <i>Scottish Medical Journal</i> , 2019, 64, 154-158.	1.3	1
26	Antiphospholipid syndrome: a clinical review. <i>Medical Journal of Australia</i> , 2019, 211, 184-188.	1.7	16
27	Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 376-386.	1.4	21
28	Clinical characteristics of patients with systemic lupus erythematosus showing a false-positive result of syphilis screening. <i>Rheumatology International</i> , 2019, 39, 1859-1866.	3.0	4
29	A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review. <i>Neurology International</i> , 2019, 11, 8182.	2.8	1
30	Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 102395.	5.8	35
31	Neurological Complications in Patients with Systemic Lupus Erythematosus. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 97.	4.2	47
32	Lupus and the Cardiopulmonary System. , 2019, , 418-433.		0
33	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibodyâ€™Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	3.4	37
34	Systemic lupus erythematosus in Native sub-Saharan Africans: A systematic review and meta-analysis. <i>Journal of Autoimmunity</i> , 2020, 106, 102348.	6.5	35
35	Managing pregnancy-associated clinical emergencies in systemic lupus erythematosus: a case-based approach. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 5-22.	3.0	3
36	Clinical management of Lupus patients during the COVID-19 pandemic. <i>Lupus</i> , 2020, 29, 1661-1672.	1.6	15
37	Early damage as measured by SLICC/ACR damage index is a predictor of hospitalization in systemic lupus erythematosus (SLE). <i>Lupus</i> , 2020, 29, 1885-1891.	1.6	3

#	ARTICLE	IF	CITATIONS
38	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	3.4	39
39	High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2020, 7, 581336.	2.6	11
40	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	3.4	60
41	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	1.6	28
42	Clinical manifestations and maternal and perinatal outcomes in pregnant women with obstetric antiphospholipid syndrome at a high complexity institution: Descriptive study. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2020, 27, 73-79.	0.0	0
43	Rare pulmonary embolism caused by the combination of bilateral popliteal venous aneurysms and antiphospholipid syndrome. <i>BMJ Case Reports</i> , 2020, 13, e236341.	0.5	2
44	Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. <i>Lupus</i> , 2020, 29, 1556-1565.	1.6	19
45	Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 3770-3777.	1.9	20
46	Anti-“Domain I” ² -Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 1242-1252.	1.3	24
47	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Blood</i> , 2021, 137, 299-309.	1.4	15
48	Pulmonary manifestations of systemic lupus erythematosus. , 2021, , 521-529.		0
49	Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?. <i>Biomedicines</i> , 2021, 9, 132.	3.2	11
50	Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century—“an observational study from the Lupus-Cruces cohort. <i>Rheumatology</i> , 2021, 61, 249-257.	1.9	7
51	Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1717-1727.	2.8	44
52	Association of antiphospholipid antibodies with clinical activity and renal pathological activity in patients with lupus nephritis. <i>Lupus</i> , 2021, 30, 1140-1145.	1.6	3
53	Lupus anticoagulant-hypoprothrombinaemia syndrome: subdural haematoma as an unusual and initial manifestation. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 306-309.	0.7	4
54	Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system. <i>Autoimmunity Reviews</i> , 2021, 20, 102796.	5.8	21
55	Cognitive Dysfunction in Systemic Lupus Erythematosus: Immunopathology, Clinical Manifestations, Neuroimaging and Management. <i>Rheumatology and Therapy</i> , 2021, 8, 651-679.	2.3	26

#	ARTICLE	IF	CITATIONS
56	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5397-5407.	1.9	48
57	Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia in Association with Antiphospholipid Syndrome. <i>Acta Haematologica</i> , 2021, 144, 1-4.	1.4	2
58	Modern View on the Problem of Systemic Lupus Erythematosus with and without Comorbid Lesions of the Circulatory System (Literature Review, Clinical Case Description) (first notice). <i>Lviv Clinical Bulletin</i> , 2021, 1-2, 37-50.	0.2	1
59	Long-term prognosis of vascular access in hemodialysis patients with systemic lupus erythematosus: a retrospective cohort study. <i>Scientific Reports</i> , 2021, 11, 12519.	3.3	0
60	Neurologic Manifestations of the Antiphospholipid Syndrome – an Update. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 41.	4.2	26
61	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1251-1266.	0.6	11
62	Systemic Lupus Erythematosus Research: A Bibliometric Analysis over a 50-Year Period. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7095.	2.6	40
63	Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study. <i>Lupus</i> , 2021, 30, 1983-1990.	1.6	9
64	Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?. <i>Biomedicines</i> , 2021, 9, 1170.	3.2	14
65	Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus: a case-based review. <i>Future Cardiology</i> , 2021, 17, 985-990.	1.2	2
66	Impact of menopause on women with systemic lupus erythematosus. <i>Maturitas</i> , 2021, 154, 25-30.	2.4	3
67	Autoimmune diseases: Sex and gender evidence in rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis. , 2021, , 53-73.		1
68	Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers. <i>Biomedicines</i> , 2021, 9, 122.	3.2	5
69	Dyspnoea in lupus. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220162.	0.5	2
70	Screening epitopes on systemic lupus erythematosus autoantigens with a peptide array. <i>Oncotarget</i> , 2017, 8, 85559-85567.	1.8	6
71	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2020, 7, 3-12.	0.6	26
72	Drug-Induced Lupus, a One-time Hit or a Harbinger of Future Autoimmunity: A Case Report. , 2020, 24, .		1
73	Netosis in the pathogenesis of antiphospholipid syndrome and systemic lupus erythematosus. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 96-102.	0.5	0

#	ARTICLE	IF	CITATIONS
74	Definition and Epidemiology of Antiphospholipid Syndrome. , 2017, , 147-169.		1
75	Antiphospholipid Syndrome: What Should Patients Know?. , 2017, , 341-357.		1
76	Sex-differentiated Incidence of Autoimmune Diseases in Women and Association with Cardiovascular Risk. <i>Cardiologia Croatica</i> , 2018, 13, 263-269.	0.0	0
77	Kidney damage associated with anti-phospholipid syndrome. <i>PoÅki</i> , 2019, 8, 161-173.	0.4	4
78	Mean Platelet Volume as Marker of Thrombosis Event in Antiphospholipid Syndrome Patients. <i>Indonesian Journal of Clinical Pathology</i> , 2019, 26, .	0.1	0
79	Features of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus. <i>UkraÅnsËkij Å¾urnal Medicini BÅ-ologÅ-Å Ta Sportu</i> , 2021, 6, 199-203.	0.2	0
80	Manifestaciones clÅnicas y desenlaces maternos y perinatales en gestantes con sÅndrome antifosfolÅpido obstÅtrico de una instituciÅn de alta complejidad: estudio descriptivo. <i>Revista Colombiana De ReumatologÅa</i> , 2020, 27, 73-79.	0.1	0
81	Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab093.	0.7	1
82	Secondary vasculopathy due to catastrophic antiphospholipid syndrome. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, , .	0.2	1
83	A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 311-329.	6.5	5
84	Identification of Mitofusin 1 and Complement Component 1q Subcomponent Binding Protein as Mitochondrial Targets in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1193-1203.	5.6	13
85	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. <i>Seminars in Immunopathology</i> , 2022, 44, 347-362.	6.1	67
86	Anticardiolipin antibodies and Lupus anticoagulant; prevalence in pregnant patients with recurrent miscarriages. <i>American Journal of Health, Medicine and Nursing Practice</i> , 2022, 7, 8-15.	0.1	0
87	Anti-Nuclear Antibodies Patterns in Patients With Systemic Lupus Erythematosus and Their Correlation With Other Diagnostic Immunological Parameters. <i>Frontiers in Immunology</i> , 2022, 13, 850759.	4.8	11
88	Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients. <i>Rheumatology</i> , 2022, 61, 3627-3639.	1.9	11
90	Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. <i>RMD Open</i> , 2022, 8, e002079.	3.8	9
91	Introductory Chapter: Antiphospholipid Antibodies - A Laboratory Criterion for the Antiphospholipid Syndrome, but Also Bystanders in Infections, Cancer, and Other Conditions. , 0, , .		0
92	Managing connective tissue disease: how to select and facilitate successful transplantation. <i>Current Opinion in Organ Transplantation</i> , 2022, 27, 191-197.	1.6	1

#	ARTICLE	IF	CITATIONS
93	Disability and cognitive impairment are interdependent in primary antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 1104-1113.	1.6	2
94	Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2136-2150.	3.8	18
95	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€˜Registryâ€™™). <i>Lupus Science and Medicine</i> , 2022, 9, e000633.	2.7	9
96	Heart arrest due to systemic lupus erythematosus relapse: case report. <i>Seminars in Cardiovascular Medicine</i> , 2022, 28, 1-4.	0.3	0
97	Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	9
98	Insights into the role of neutrophils in neuropsychiatric systemic lupus erythematosus: Current understanding and future directions. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
99	Antiphospholipid Antibodies in Pregnancy: Maternal and Neonatal Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 337-347.	2.7	2
100	Digital ulcers as presenting symptom of secondary antiphospholipid syndrome. <i>JAAD Case Reports</i> , 2022, 29, 1-5.	0.8	1
101	Risk of livedo with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Lupus</i> , 2022, 31, 1595-1605.	1.6	4
102	Factors mediating cancer risk in systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 1285-1295.	1.6	3
103	Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
104	Pathophysiological Changes in the Hemostatic System and Antithrombotic Management in Kidney Transplant Recipients. <i>Transplantation</i> , 0, Publish Ahead of Print, .	1.0	1
105	Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6578.	4.1	8
106	Role of <sc>Plateletâ€Bound</sc> C4d (<sc>PC4d</sc>) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 2088-2095.	3.4	1
107	Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. <i>BMJ, The</i> , 0, , e069717.	6.0	33
108	The diagnostic laboratory tests in rheumatic diseases. , 2023, , 113-148.		0
109	Challenges in systemic lupus erythematosus: From bench to bedside. , 2023, , 293-331.		1
110	An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus. <i>Biomolecules</i> , 2023, 13, 617.	4.0	1

#	ARTICLE	IF	CITATIONS
111	A rare simultaneous presentation of combined occlusion and optic neuritis in a lupus erythematosus patient with anti-phospholipid antibody syndrome. <i>Lupus</i> , 2023, 32, 804-809.	1.6	1
112	Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades. <i>Biomedicines</i> , 2023, 11, 1218.	3.2	2
114	High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
115	An update on the biologics for the treatment of antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
116	Triphasic: Preeclampsia, Systemic Lupus Erythematosus, and Severe Neutropenia With Use of Granulocyte Colony Stimulating Factor in the Partum and Postpartum Period. <i>Arthritis Care and Research</i> , 2023, 75, 2036-2043.	3.4	1
117	Maternal Medical Disorders of Fetal Significance. , 2024, , 82-98.e4.		0
118	Organ damage in Systemic Lupus Erythematosus patients: A multifactorial phenomenon. <i>Autoimmunity Reviews</i> , 2023, 22, 103374.	5.8	3
119	Clinicopathologic characteristics and outcomes of late onset lupus nephritis: a single centre experience. <i>Rheumatology International</i> , 0, , .	3.0	0
120	Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!. <i>Medicina (Lithuania)</i> , 2023, 59, 1169.	2.0	2
121	Bleeding and thrombotic events in a patient with lupus anticoagulant-associated hypoprothrombinemia and antiphospholipid antibody syndromes: managing hemostasis between Scylla and Charybdis. <i>Internal and Emergency Medicine</i> , 2023, 18, 1233-1238.	2.0	1
122	Choice of anticoagulation in patients with low risk antiphospholipid syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 121-127.	2.1	1
123	Neural Regeneration in Dry Eye Secondary to Systemic Lupus Erythematosus Is Also Disrupted like in Rheumatoid Arthritis, but in a Progressive Fashion. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10680.	4.1	2
124	Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report. <i>Journal of Rheumatology</i> , 2024, 51, 150-159.	2.0	6
125	Anti-Phospholipid Antibodies in Women with Placenta-Mediated Complications Delivered at >34 Weeks of Gestation. <i>Journal of Clinical Medicine</i> , 2023, 12, 4516.	2.4	0
126	A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and Its Autoimmune Disease Associations. <i>Cureus</i> , 2023, , .	0.5	0
128	French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children. <i>Revue De Medecine Interne</i> , 2023, 44, 495-520.	1.0	0
129	Pericardial and mediastinal fat-associated lymphoid clusters are rapidly activated in an alkane-induced model of systemic lupus erythematosus. , 2023, 2, .		0
130	Evaluation of acquired and hereditary risk factors for the development of thromboembolism in patients with systemic lupus erythematosus. <i>Blood Coagulation and Fibrinolysis</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
131	Risk factors and recurrent thrombosis in primary antiphospholipid syndrome. Exploration of Immunology, 0, , 475-489.	0.3	0
132	Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus " A proposal from an expert panel. Autoimmunity Reviews, 2023, 22, 103479.	5.8	0
133	An Emerging Role for Anti-DNA Antibodies in Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2023, 24, 16499.	4.1	0
134	How I diagnose and treat antiphospholipid syndrome in pregnancy. Blood, 2024, 143, 757-768.	1.4	0
135	Implications of Inflammatory Processes on a Developing Central Nervous System in <scp>Childhood"€Onset</scp> Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2024, 76, 332-344.	5.6	0
136	Vascular damage in systemic lupus erythematosus. Nature Reviews Nephrology, 2024, 20, 251-265.	9.6	1
137	Contraception in Women with Lupus Autoimmune Diseases. , 2024, , 187-191.		0
138	GC/MS and LC/MS serum metabolomic analysis of Chinese LN patients. Scientific Reports, 2024, 14, .	3.3	0
139	A case of systemic lupus erythematosus in a patient with Noonan syndrome with recurrent severe hypoglycaemia. Modern Rheumatology Case Reports, 0, , .	0.7	0
140	Female patients with systemic lupus erythematosus (SLE)-associated antiphospholipid syndrome (APS) have a lower ovarian reserve than either primary APS or SLE patients. Journal of Laboratory Medicine, 2024, 48, 83-90.	1.1	0
141	The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus. Rheumatology, 2024, 63, S172-S185.	1.9	1